Skip to content
Search

Latest Stories

First ever drug for alopecia hair loss disorder which affects Jada Pinkett Smith and thousands of Brits to get funded by NHS

The drug is called baricitinib, and it is already in use on the NHS for a number of conditions, including arthritis, dermatitis, and even severe Covid.

First ever drug for alopecia hair loss disorder which affects Jada Pinkett Smith and thousands of Brits to get funded by NHS

The first-ever drug for alopecia hair loss gets the green signal as the NHS considers funding it.

Alopecia, which is a hair loss condition affects roughly 40% of women, and 30% of men at some point in their lives. Hollywood star Jada Pinkett Smith and 100,000 Britons are also affected by this debilitating condition.


The drug is called baricitinib, and it is already in use on the NHS for a number of conditions, including arthritis, dermatitis, and even severe Covid. Baricitinib has been proven to regrow hair.

The drug works by interrupting faulty signals that make the immune system attack hair follicles, the Daily Mail informs.

Trials have reportedly shown that taking the daily pill can almost entirely reverse the condition that causes hair to fall out in clumps.

Charities and doctors celebrated the good news of the funding of the drug, and have now called for the NHS to pay for those with the most severe form of alopecia to receive the drug as soon as possible.

Sue Schilling, chief executive of the charity Alopecia UK is reported to have said, “This is a really important step in the right direction for a group of patients who up until now had no effective treatment options.”

She adds, “Alopecia is an incredibly debilitating condition that leaves people depressed, anxious, and sometimes even suicidal. The NHS needs to fund this, so patients can receive it for free.”

It is reported that about 100,000 Britons have a condition called alopecia areata, where cells in the immune system attack hair follicles, and the reasons for this are not understood.

Over a period of weeks, the hair begins to come out in clumps, and this results in bald patches. Some people have been known to even lose their eyebrows, eyelashes, and hair elsewhere on the body.

Steroid treatments can be prescribed to treat alopecia and are effective in one in five patients. However, steroid pills long-term can dramatically increase the risk of serious conditions such as type 2 diabetes.

Therefore, doctors advise patients to stop taking them after six weeks. Additionally, steroid creams can irritate the skin and cause migraines.

On the other hand, Baricitinib which is a part of a family of drugs called JAK inhibitors can be taken daily and continued indefinitely.

Unlike steroid drugs, this medication does not attack healthy immune cells, and thus the side effects are usually minimal.

Studies show that for a third of patients, the drug baricitinib sparks hair regrowth within three months and it continues to grow back.

Patients who respond to the treatment have reportedly seen 80% of their hair get restored.

“Given the clear benefits, it's likely that people with the most severe form of alopecia will soon be able to access baricitinib,” Dr Paul Farrant, consultant dermatologist at University Hospitals Sussex NHS Foundation Trust, said.

Dr Farrant who is reported to have given baricitinib to more than 30 patients, is quoted as saying, “For those who respond, the effects can be transformative. They go from no hair to full hair.”

However, due to the drug’s effectiveness, some dermatology clinics are reportedly offering patients baricitinib at a cost of £1,000 a month and charities are concerned this high price is forcing many to buy the drug out of the country.

“We've heard of a number of people buying it from overseas and taking it without medical supervision,' says Schilling.

“Taking a drug like this in large doses can be unsafe, especially without monitoring. This could be avoided if the treatment is available on the NHS,” she said.

Tyson Braun, 37, from Milwaukee, Wisconsin is someone who has benefitted from baricitinib. He reportedly began to lose his hair at the age of 25, after suffering from the flu. He is quoted as saying, “At first, it was just patches on my beard. Then the hair on my head was coming out too. Within a year I didn't have any hair anywhere on my body.”

Tyson tried a number of treatments but all were unsuccessful. However, two months ago, he got lucky and got a prescription for baricitinib.

Speaking about the transformation he said, “There's already hair sprouting on my face, where I used to have a beard. And there's even a bit on my head.

“Every day it feels like there's more. I never expected to have hair again. My two sons have only ever known me as bald. 'It will take some explaining when it grows out even more.”

More For You

Parliament backs assisted dying in historic law shift

Supporters of the assisted dying law for terminally ill people hold a banner, on the day British lawmakers are preparing to vote on the bill, in London, Britain, June 20, 2025. REUTERS/Isabel Infantes

Parliament backs assisted dying in historic law shift

PARLIAMENT voted on Friday (20) in favour of a bill to legalise assisted dying, paving the way for the country's biggest social change in a generation.

314 lawmakers voted in favour with 291 against the bill, clearing its biggest parliamentary hurdle.

Keep ReadingShow less
Air India

An Air India Airbus A320-200 aircraft takes off from the Sardar Vallabhbhai Patel International Airport in Ahmedabad, India, July 7, 2017. Picture taken July 7, 2017.

Regulator warns Air India over delayed emergency equipment checks: Report

INDIA’s aviation regulator has warned Air India for violating safety rules after three of its Airbus aircraft operated flights without undergoing mandatory checks on emergency escape slides, according to official documents reviewed by Reuters.

The Directorate General of Civil Aviation (DGCA) issued warning notices and a detailed investigation report highlighting the breach. These documents were sent days before the recent crash of an Air India Boeing 787-8, in which all but one of the 242 people onboard were killed. The Airbus incidents are unrelated to that crash.

Keep ReadingShow less
assisted dying bill

Pro and anti-assisted dying campaigners protest ahead of a parliamentary decision later today, on June 20, 2025 in London.

Getty Images

MPs to vote on assisted dying bill amid divided views

UK MPs are set to hold a key vote on assisted dying on Friday, which could either advance or halt a proposed law that would allow terminally ill adults to end their lives under strict conditions.

The vote follows several hours of debate in the House of Commons and will decide whether the Terminally Ill Adults (End of Life) Bill moves to the House of Lords for further scrutiny or is dropped altogether.

Keep ReadingShow less
Zhenhao Zou

Zhenhao Zou, 28, was jailed on Thursday after being found guilty of multiple offences. (Photo: Reuters)

Reuters

Chinese student jailed for life for raping women in UK and China

A CHINESE postgraduate student convicted of drugging and raping 10 women in the UK and China has been sentenced to life imprisonment by a London court.

Zhenhao Zou, 28, was jailed on Thursday after being found guilty of multiple offences. Police say there is evidence he may have targeted more than 50 other women.

Keep ReadingShow less
Air India cuts international flights after deadly crash

Mother (C) of First Officer Clive Kunder, co-pilot of the Air India plane that crashed in Ahmedabad last week, mourns after his mortal remains were brought to his residence, in Mumbai. (PTI Photo)

Air India cuts international flights after deadly crash

AIR INDIA said on Wednesday (18) it will cut international operations on its widebody aircraft by 15 per cent for the next few weeks, citing ongoing safety inspections and operational disruptions following last week's deadly crash of one of its Boeing 787 Dreamliners.

Authorities continue to investigate the crash of flight AI171, which killed 241 people and marked the world's deadliest aviation disaster in a decade.

Keep ReadingShow less